MedNet To Showcase The iMedNet Partner Program At Partnerships in Clinical Trials 2014
MedNet will once again be participating in the Partnerships in Clinical Trials conference.
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, will once again be participating in the Partnerships in Clinical Trials conference. This year's event will be held March 30 – April 2 in Las Vegas, Nevada. Attendees are encouraged to visit MedNet's booth to see iMedNet EDC – an incredibly flexible and user friendly SaaS-based eClinical technology platform – and learn about the iMedNet Partner Program, created specifically to support the success of Clinical Research Organizations (CROs) and other healthcare consultants.
Key benefits of the iMedNet Partner Program include:
- Predictable and Affordable Pricing
- Plus special partners-only discounts
- Full Sales and Marketing Support
- From sales training to prospective customer referrals
- iMedNet Advisory Forum Membership
- Ensuring partners' eClinical needs are fully addressed
"This year's Partnerships conference will be an exciting one," noted John M. (Rob) Robertson, President and CEO of MedNet Solutions. "We'll have representatives on site to provide interested individuals with iMedNetdemonstrations as well as more details about our iMedNet Partner Program. Since interest in our technology solutions and wrap-around support programs is growing rapidly, we anticipate a busy, but very productive few days."
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
